Your search returned 8 results.

Results
	1.	Guidelines for the indications for 131I remnant ablation on differentiated thyroid cancer: a distillation and comparison of guidelines from seven organizations. MedStar authors: Khorjekar, Gauri Orquiza, Michael D Van Nostrand, Douglas Year: 2013 Citation: 2013/06/08/ Department: Medicine/Nuclear Medicine Form of publication: Poster Presentation All authors: Guan H, Van Nostrand D, Li Y, Orquiza M, Teng W, Khorjekar G Local accession number: 2013_235 Add to cart (remove)
	2.	Whole body retention of 131I at 24hr versus 48hr as a predictor of maximum tolerated activity (MTA). MedStar authors: Atkins, Frank Orquiza, Michael D Van Nostrand, Douglas Wartofsky, Leonard Year: 2013 Citation: 2013/06/08/ Department: Medicine/Endocrinology Medicine/Nuclear Medicine Form of publication: Poster Presentation Local accession number: 2013_231 Add to cart (remove)
	3.	Guidelines for the prescribed activity for 131I remnant ablation on differentiated thyroid cancer: a distillation and comparison of guidelines from seven organizations. MedStar authors: Khorjekar, Gauri Orquiza, Michael D Van Nostrand, Douglas Year: 2013 Citation: 2013/06/08/ Department: Medicine/Nuclear Medicine Form of publication: Poster Presentation All authors: Guan H, Van Nostrand D, Li Y, Orquiza M, Teng W, Khorjekar G Local accession number: 2013_236 Add to cart (remove)
	4.	Alpharadinr in the treatment of skeletal metastasis secondary to metastatic prostate cancer: an educational exhibit. MedStar authors: Duong, Eric Khorjekar, Gauri Orquiza, Michael D Van Nostrand, Douglas Year: 2013 Citation: 2013/06/08/ Department: Medicine/Nuclear Medicine Form of publication: Poster Presentation All authors: Duong E, Orquiza M, Khorjekar G, Van Nostrand D Local accession number: 2013_233 Add to cart (remove)
	5.	Characterization of Sialoadenitis (SA) after administration of continuous Sialogogues (SGs) during the day and night after 131I therapy (tx). MedStar authors: Acio, Elmo Burman, Kenneth D Garcia, Carlos Khorjekar, Gauri Kulkarni, Kanchan Orquiza, Michael D Schneider, Mark Wartofsky, Leonard Year: 2013 Citation: 2013/06/08/ Department: Medicine/Endocrinology Medicine/Nuclear Medicine Form of publication: Poster Presentation Local accession number: 2013_230 Add to cart (remove)
	6.	The Utility of "Blind" 131I treatments for differentiated thyroid cancer: an educational exhibit. MedStar authors: Orquiza, Michael D Van Nostrand, Douglas Year: 2013 Citation: 2013/06/08/ Department: Medicine/Nuclear Medicine Form of publication: Poster Presentation All authors: Elboga U, Orquiza M, Celen Y, Aktolun C, Van Nostrand D Local accession number: 2013_234 Add to cart (remove)
	7.	Correlation of 124I PET dosimetry with clinical response of 131I therapy (Tx) for Metastatic Differentiated Thyroid Cancer (DTC). MedStar authors: Atkins, Frank Garcia, Carlos Khorjekar, Gauri Mete, Mihriye Orquiza, Michael D Van Nostrand, Douglas Wartofsky, Leonard Year: 2013 Institution: MedStar Health Research Institute MedStar Washington Hospital Center Department: Medicine/Nuclear Medicine Form of publication: Conference All authors: Khorjekar G, Orquiza MD, Atkins F, Mete M, Garcia C, Wartofsky L, Van Nostrand D Local accession number: 2013_2 Add to cart (remove)
	8.	124I-NaI PET/CT based 3-D radiobiological Dosimetry (3D-RD) for 131I-NaI therapy of metastatic well-differentiated thyroid cancer. MedStar authors: Atkins, Frank Khorjekar, Gauri Orquiza, Michael D Van Nostrand, Douglas Van Nostrand, Douglas Year: 2013 Institution: MedStar Washington Hospital Center Department: Medicine/Nuclear Medicine Form of publication: Conference All authors: Atkins F, Khorjekar G, Orquiza MD Local accession number: 2013_2 Add to cart (remove)

Powered by Koha